logo
Your Next Shirt Could Come From CO2 – The New Worlds Of Fashion, Food

Your Next Shirt Could Come From CO2 – The New Worlds Of Fashion, Food

Forbes30-06-2025
Zara Summers w CO2 T-shirt & Joan - ED Women's Summit - 4-22-2025
'We harness the power of the tiny microbe,' Zara Summers, Ph.D. explained, 'They're eating gas, they're eating CO2, carbon monoxide and hydrogen, and they're turning them into ethanol…this is the oldest metabolism on earth.'
'These microbes are called acetogens, your oldest ancestor, if you will,' she said at The Earth Day Women's Summit on April 22, 2025 at EarthX2025 in Dallas, Texas. 'They are descendants of early life,' she said, presenting a white t-shirt (with a black swoosh on it) and a pair of fuchsia leggings that she said were made from captured CO2.
Then she continued her mini-chemistry lesson telling us how these microbes can make other things we need every day. 'They turn it into ethanol, and so all we have to do is a little bit of chemistry on the back end and take that ethanol…and you slam together and make long polymers, and those long polymers become your jet fuel. This is your sustainable aviation fuel, or as the new administration would like us to call it, synthetic aviation fuel, whatever.'
Screenshot of list of products made from petroleum - Ranken-Energy.com
The key point to me from Summers was, 'Once you have ethylene, it's actually a building block of everything that petroleum is, is used for today.'
Think about all the things made from petroleum today, beyond the gas in your car or truck. Polyester, plastic, pesticides, cement, asphalt, tires, nail polish, refrigerators, eyeglasses, aspirin, the list goes on because literally hundreds, maybe thousands of different products are made from petroleum.
Zara Summers, LanzaTech
'Pretty much any synthetic fiber that you can get from Fossil, we have a path to create.,' she said. 'Instead of pumping that carbon monoxide and dioxide directly into the atmosphere, we pump it into our massive, kind of like a brewery, but cooler, huge, huge 500,000 liter tanks of living, breathing, spinning out ethanol microbes. And so we harness that. It's a continuous process. So it's very much like a, a refining process,' is how Summers described their process in layperson's terms. She also said they are making a new edible protein out of captured CO2.
It sounds like science fiction but it's the new world of fashion and food, as innovators like Summers, who is Chief Science Officer at LanzaTech, find innovative ways to address the climate crisis.
Zara Summers explains fuchsia CO2 leggings held by Joan Michelson at The Earth Day Women's Summit - ... More 4-22-2-25
They have 'partnered with REI' on running apparel, with Gucci on perfume, and with Athleta on those leggings, as well as with Lululemon and 'a lot of brands.' Athleta, she said, 'committed that they want to hit about 25% of the polyester that they're, of the carbon that is going into these leggings, is going to be from emissions produced ethanol. This is a massive step change.'
'This is about giving women knowledge and skills about climate change. Before we talked to these women, they actually thought that climate change was a divine intervention and they didn't understand it. They had no idea that the changes that they were seeing were due to weather patterns. They thought it was something that was more divine,' Alison Ward, CEO of CottonConnect explained at the Summit. CottonConnect is a nonprofit that trains and empowers female farmers in India, China, Pakistan, Turkey, Egypt, and Bangladesh to grow cotton sustainably, and financially sustainable businesses. They have deals with Primark and Carrefour (in Europe), among others.
'These women are quite near big urban centers, but just haven't had access to training and knowledge,' she added.
Screenshot - Woman in cotton field on CottonConnect.org
These female farmers face 117 degree heat Fahrenheit, and changes in their water sources, and their cattle not producing as much milk, among other consequences of climate change, Ward delineated.
The techniques CottonConnect teaches the women to use often originate in indigenous cultures, she said. 'So, we're almost going back to some original techniques that we are rediscovering,' including how to make natural pesticides with things already on their farm. King Charles III uses one on his sheep, she offered intriguingly.
'There's the positive impact on from regenerative, but also there's that sort of positive impact in terms of the status of women in these communities,' Ward emphasized. These women have more influence.
Screenshot - TraceBale - CottonConnect.org
CottonConnect and the farmers can track where their cotton is used, because they give every farm a tracking system, including a DNA marker, which enables them to track their cotton through the supply chain to your local retailer. They have traced 1.7 billion t-shirts, so far, she disclosed.
'We know that globally we have enough production on planet Earth in order to ensure proper nutrition – and again, nutrition's very different from caloric and a full belly, as we know from all of the health issues that are more in developed worlds. But, there's serious distribution problems,' Robin Currey, Ph.D. explained on the panel.
Connecticut Food Bank
That means, 'that not everybody has equitable access to the kinds of foods that they need and want, at the times that they need them. So there's, there's quite a bit of instability,' Currey cautioned. She is a professor focused on sustainable food systems, and Vice President for Academic Affairs at Southwestern University.
What are 'food systems'? As Currey explained, 'food systems have to do with everything, from production to processing, distribution, the utilization. So that's like how we prepare it, how we're cooking it,' and of course food waste.
David Lemons, left, and Leo Brito unload discarded food as its mixed in to start a 12-month ... More competing process at Zero Waste Houston, Tuesday, Nov. 21, 2023, in Conroe. (Jason Fochtman/Houston Chronicle via Getty Images)
Unfortunately, food waste in the United States is a massive 40%. Talk about a distribution problem; think about all the hungry people that 40% of wasted food – or even half of it – could feed if it was distributed to those who need it.
These remarkable innovations are driven by the challenge to address the climate crisis and make our lives better. They also empower women as both businesspeople and consumers.
Consumers have a lot power with our purchases, especially women, who make or influence 85% of them.
Listen to the full Earth Day Women's Summit panel, and individual interviews with Robin Currey, Zara Summers, and Alison Ward on Electric Ladies Podcast.
A woman searches for a sweater at a Uniqlo store on January 4, 2025 in New York City. (Photo by ... More)
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns
Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns

Yahoo

time7 hours ago

  • Yahoo

Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns

Key Points CRISPR Therapeutics' first approved therapy, Casgevy, was a breakthrough. One of Casgevy's biggest achievements may be demonstrating the viability of CRISPR Therapeutics' strategy. The biotech company could soar if it can follow up that win with more clinical and regulatory milestones. 10 stocks we like better than CRISPR Therapeutics › Over the past few years, the market hasn't been kind to somewhat speculative, unprofitable stocks. CRISPR Therapeutics (NASDAQ: CRSP), a mid-cap biotech, fits that description. The company's shares are down by 24% since mid-2022. The S&P 500 is up 50% over the same period. Despite this terrible performance, there are reasons to believe that CRISPR Therapeutics could still generate life-changing returns for investors willing to be patient. Here's how the biotech could pull it off. CRISPR Therapeutics' first success CRISPR Therapeutics' first approval was for Casgevy, a treatment for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT), which it developed in collaboration with Vertex Pharmaceuticals. Before Casgevy, no CRISPR-based gene-editing medicine had been approved. While it became the first, it still faces some challenges. Ex vivo gene-editing therapies require a complex manufacturing and administration process that can only be performed in authorized treatment centers (ATCs). Moreover, they're expensive. Casgevy costs $2.2 million in the U.S. Getting third-party payers on board for that is no easy feat. Still, CRISPR Therapeutics and Vertex Pharmaceuticals are making steady progress. As of the second quarter, CRISPR Therapeutics had achieved its goal of activating 75 ATCs. It had also secured reimbursement for eligible patients in 10 countries. The two companies estimate there are roughly 60,000 eligible SCD and TDT patients in the regions they have targeted. Let's say they continue to strike reimbursement deals and can count on third-party coverage for 70% of this target population (42,000 people), then go on to treat another 30% of that group in the next decade (12,600 patients). Assuming they could extend that $2.2 million price tag to those countries, Casgevy could generate more than $27.7 billion over this period. Based on its agreement with Vertex, 40% would go to CRISPR Therapeutics, or roughly $11.1 billion over a decade. That's not bad, but it's not that impressive either. So, while Casgevy could contribute meaningfully to CRISPR Therapeutics' results -- and may even reach blockbuster status at some point -- the medicine may primarily serve as a proof of concept to demonstrate that the biotech's approach can be effective. Substantial progress with its first commercialized product will help the stock price. But the company's performance will depend even more on future clinical and regulatory milestones, especially as it shows with Casgevy that it can manage the intricacies and complexities of marketing gene-editing medicines. Can the pipeline deliver? CRISPR Therapeutics has six candidates in clinical trials, which isn't bad at all for a mid-cap biotech company. One of its leading programs is CTX310, a potential therapy designed to help reduce low-density lipoprotein (LDL) cholesterol in patients with certain conditions. CTX310 is already producing encouraging clinical trial results. Additionally, it's an in vivo medicine, meaning it bypasses the need to harvest patients' cells to manufacture therapies; in vivo gene-editing treatments are easier to handle than their ex vivo counterparts. The company's path to creating life-changing returns hinges on its ability to deliver consistent clinical and regulatory wins over the next few years for CTX310 and other important candidates. If CRISPR Therapeutics can successfully launch several new products in the next five to seven years, its shares are likely to skyrocket. In the meantime, under this scenario, the company would succeed in making gene-editing medicines more mainstream. This would encourage third-party payers to get on board -- and healthcare institutions, and perhaps even governments, to help push for more ATCs, since there'd be a greater need to accommodate these treatments. Can CRISPR Therapeutics achieve this? In my view, the biotech stock is on the riskier side, but does carry significant upside potential. There's a (small) chance the gene-editing specialist will deliver life-changing returns in the next decade, but investors need to hedge their bets. It's best to start by initiating a small position in the stock, then progressively add more if CRISPR Therapeutics lands more wins. Should you invest $1,000 in CRISPR Therapeutics right now? Before you buy stock in CRISPR Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and CRISPR Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Prosper Junior Bakiny has positions in Vertex Pharmaceuticals. The Motley Fool has positions in and recommends CRISPR Therapeutics and Vertex Pharmaceuticals. The Motley Fool has a disclosure policy. Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns was originally published by The Motley Fool

Kumail Nanjiani recalls meeting Elon Musk while shooting 'Silicon Valley':' ''He didn't like the show'
Kumail Nanjiani recalls meeting Elon Musk while shooting 'Silicon Valley':' ''He didn't like the show'

Yahoo

time8 hours ago

  • Yahoo

Kumail Nanjiani recalls meeting Elon Musk while shooting 'Silicon Valley':' ''He didn't like the show'

Kumail Nanjiani said that Elon Musk was "upset" with the opening scene of Silicon Valley. Nanjiani appeared on an episode of Mike Birbiglia's podcast Working It Out, where he recalled some of the experiences he had with tech giants while on the show. "He didn't like the show," Nanjiani said of Musk. The Eternals actor remembered meeting the Tesla CEO, who said the parties he attended were "much cooler" than those depicted on Silicon Valley. The premiere opens with Kid Rock playing at a tech event to a sparse, dead crowd. "It was like, 'Yeah, man. You're one of the richest people in the world. We're, like, losers on the show. Of course your parties are better than my parties. What are you talking about?'" the Big Sick star said. The comedian also met Mark Zuckerberg while doing the show, but made a bad impression. He and his costar Martin Starr had presented at the Breakthrough Awards, which were co-founded by Zuckerberg, in 2016. During the ceremony, the Silicon Valley actors called back to a joke from the season 1 finale about giving hand jobs to an entire conference room of people. They retooled that bit to accommodate the number of scientists at the Breakthrough Awards and bombed. Nanjiani said he doesn't blame the Facebook founder for disliking him after that moment. "He was like, 'What the f--- was that?'" Nanjiani said. "And truly in that moment he was right." Check out the full episode of Working It Out with Kumail Nanjiani below. Read the original article on Entertainment Weekly

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store